Cabaletta Bio

$15.53
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.

+$0.58 (+3.88%) Today
$0.00 (0.00%) As of 6:01 PM EST after-hours

Why Robinhood?

You can buy or sell Cabaletta Bio and other stocks, options, and ETFs commission-free!

About CABA

Cabaletta Bio, Inc. operates as a clinical-stage biotechnology company, which engages in the discovery and development of engineered T cell therapies for B cell-mediated autoimmune diseases. Its proprietary technology utilizes chimeric autoantibody receptor to selectively bind and eliminate B cells that produce disease-causing autoantibodies. The company was founded by Michael C. Milone, Steven Nichtberger, and Aimee Payne in April 2017 and is headquartered in Philadelphia, PA. The listed name for CABA is Cabaletta Bio, Inc. Common Stock.

CEO
Steven Nichtberger
Employees
22
Headquarters
Philadelphia, Pennsylvania
Founded
2017
Market Cap
373.58M
Price-Earnings Ratio
Dividend Yield
Average Volume
57.06K
High Today
$15.72
Low Today
$15.00
Open Price
$15.00
Volume
31.12K
52 Week High
$19.63
52 Week Low
$5.51

Collections

CABA Earnings

-$0.65
-$0.43
-$0.22
$0.00
Q4 FY19
Q1 FY20
Q2 FY20
Q3 FY20
Q4 FY20
Estimated
per share
Actual
Expected Mar 29, Pre-Market

You May Also Like